Love The One You’re With: BMS Pays Exelixis $240M Upfront In New Cancer Drug Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Exelixis re-partners with long-term collaborator BMS the same late-stage XL184 that GSK rejected less than two months earlier.
You may also be interested in...
Exelixis Reorganizes R&D And Cuts Its Workforce By 40 Percent
The biotech hopes to advance three late-stage compounds and others into development, but the overall tally will be reduced for the foreseeable future.
Exelixis Reorganizes R&D And Cuts Its Workforce By 40 Percent
The biotech hopes to advance three late-stage compounds and others into development, but the overall tally will be reduced for the foreseeable future.
Reimbursement Risks Driving Contingency-Based Deals, GSK Exec Says
Big pharma's appetite for low-cost, low-risk deals won't abate in 2010, as drug makers look to hedge their development bets and smaller companies need financing alternatives in a cash-constrained environment